Skip to content
Tech News
clear
Topics: Today This Week This Month This Year
1.
Gilead Sciences Swings to Loss on R&D Costs as HIV-Drug Sales Lift Revenue (feeds.content.dowjones.io)
2.
‘The Testaments’ Stars on Finding Tenderness Amid Gilead’s Horrors (gizmodo.com)
3.
‘The Testaments’ Has Been Renewed for Season 2 (gizmodo.com)
4.
Cramer's lightning round: Nokia still has room to run (cnbc.com)
5.
The Wicked Stepmother of ‘The Testaments’ Is So Much Fun to Hate (gizmodo.com)
6.
Gilead to Buy German Biotech Tubulis for $3 Billion for Experimental Cancer Drugs (feeds.content.dowjones.io)
7.
Gilead Sciences to Buy Clinical-Stage Biotech Tubulis for Up to $5 Billion (feeds.content.dowjones.io)
8.
The ‘Handmaid’s Tale’ Sequel Is a Beautifully Executed Dystopian Nightmare (gizmodo.com)
9.
Gilead Sciences to Buy Ouro Medicines, Collaborate With Galapagos on Purchased Assets (feeds.content.dowjones.io)
10.
Gilead Sciences to Buy Ouro Medicines for Up to $2.18 Billion (feeds.content.dowjones.io)
11.
FDA has approved Yeztugo, a drug that provides protection against HIV infection (news.ycombinator.com)
12.
The first 100% effective HIV prevention drug is approved and going global (news.ycombinator.com)
13.
FDA Approves ‘Breakthough’ Drug to Prevent HIV (gizmodo.com)
Today's top topics: google pixel 11 tensor g6 trump administration pixel watch 5 apple tv kospi chatgpt gemini promo codes
View all today's topics →